NIH RECOVER: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults

Status: Active_not_recruiting
Location: See all (86) locations...
Study Type: Observational
SUMMARY

This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

∙ INFECTED COHORT -- ADULTS WITH SUSPECTED SARS-COV-2 INFECTION --

∙ An adult qualifies as having suspected SARS-CoV-2 infection if meeting criteria a, b or c below:

⁃ Patients who meet the following clinical criteria plus one of the epidemiological criteria:

⁃ Clinical Criteria: Acute onset of fever and cough OR acute onset of any three of more of the following signs or symptoms: fever, cough, general weakness /fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status.

⁃ Epidemiological Criteria:

‣ Residing or working in an area with a high risk of transmission of virus: closed residential settings, humanitarian settings such as camp and camp-like settings for displaced persons; anytime within the 14 days before symptom onset; or

‣ Residing or travel to an area with community transmission anytime within the 14 days before symptom onset; or

‣ Working in any health care setting, including within health facilities or within the community; anytime within the 14 days before symptom onset.

⁃ A patient with severe acute respiratory illness: (acute respiratory infection with history of fever or measured fever of ≥38C°; and cough; with onset within the last 10 days; and requires hospitalization).

⁃ An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2 Antigen-RDT.

∙ ADULTS WITH PROBABLE SARS-COV-2 INFECTION --

∙ An adult qualifies as having probable SARS-CoV-2 infection if meeting any one of a-d below:

⁃ A patient who meets clinical criteria for suspected SARS-CoV-2 AND is a contact of a probable or confirmed case or linked to a COVID-19 cluster;

⁃ A suspect case with chest imaging showing findings suggestive of COVID-19 disease;

⁃ A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified cause;

⁃ Death, not otherwise explained, in an adult with respiratory distress preceding death AND was a contact of a probable or confirmed case or linked to a COVID-19 cluster

∙ ADULTS WITH CONFIRMED SARS-COV-2 INFECTION --

∙ An adult qualifies as having confirmed SARS-CoV-2 infection if meeting any one of a-d below:

⁃ Any person with a positive Nucleic Acid Amplification Test (NAAT);

⁃ Any person with a positive SARS-CoV-2 Antigen-RDT OR positive SARS-CoV-2 antibody test\* AND meeting either the probable case definition or suspect criteria A OR B;

⁃ An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who is a contact of a probable or confirmed case

⁃ Any person with a positive SARS-CoV-2 nucleocapsid protein antibody test OR a positive SARS-CoV-2 spike protein antibody test IF not vaccinated

‣ (\*)This protocol modifies the WHO criterion b to add detectable SARS-CoV-2 antibody as a qualifying test.

∙ UNINFECTED COHORT -- ADULTS WITH NO SARS-COV-2 INFECTION --

• Does not meet WHO criteria for a suspected, probable, or confirmed case of SARS-CoV-2 infection, AND

• Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen in the past, if being enrolled as a post-acute control (see XII.H), AND

• Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen at the time of enrollment/screening, AND

• Has a negative SARS-CoV-2 nucleocapsid protein antibody and spike protein antibody test (spike only if not vaccinated) at the time of enrollment, AND

• Live in the same communities or recruited from the same sources as those in the SARS-CoV-2 infected cohort, AND

• Note: uninfected individuals may participate independent of their vaccination status

Locations
United States
Alabama
University of Alabama at Birmingham
Birmingham
University of Alabama at Birmingham (Pregnancy Cohort)
Birmingham
University of South Alabama
Mobile
Arizona
Banner University Medical Center (BUMC) - Phoenix
Phoenix
University of Arizona
Tucson
California
Cedars-Sinai Medical Center
Los Angeles
University of California San Francisco (Pregnancy Cohort)
San Francisco
University of California, San Francisco (UCSF)
San Francisco
Stanford University
Stanford
Colorado
Denver Health and Hospital Authority
Denver
University of Colorado Denver
Denver
Connecticut
Yale School of Medicine (YSM)
New Haven
Washington, D.c.
George Washington University
Washington
Howard University
Washington
Delaware
ChristianaCare Health System
Newark
Georgia
Emory University
Atlanta
Kaiser Permanente Georgia
Atlanta
Morehouse School of Medicine (MSM)
Atlanta
Hawaii
University of Hawai'i - Mānoa's John A. Burns School of Medicine
Honolulu
Illinois
University of Illinois at Chicago
Chicago
Northwestern University
Evanston
Northshore University HealthSystem
Glenview
Kansas
University of Kansas Medical Center (KUMC)
Kansas City
Kentucky
University of Kentucky
Lexington
Louisiana
Louisiana State University - Pennington Biomedical Research Center
Baton Rouge
Louisiana State University (LSU)
New Orleans
Ochsner Health System
New Orleans
Tulane University
New Orleans
University Medical Center New Orleans
New Orleans
Massachusetts
Beth Israel Deaconess Medical Center (BIDMC)
Boston
Boston University
Boston
Brigham and Women's Hospital
Boston
Harvard Medical School
Boston
Harvard School Of Public Health
Boston
Mass General Brigham - Harvard University
Boston
Massachusetts General Hospital
Boston
Tufts Medical Center
Boston
Cambridge Health Alliance (CHA)
Cambridge
Maine
MaineHealth
Portland
Minnesota
Mayo Clinic
Rochester
Mississippi
University of Mississippi Medical Center (UMMC)
Jackson
North Carolina
University of North Carolina (UNC) at Chapel Hill
Chapel Hill
Duke University Medical Center
Durham
WakeMed Health & Hospitals
Raleigh
North Dakota
University of North Dakota
Grand Forks
Nebraska
University Of Nebraska Medical Center
Omaha
New Jersey
Saint Peter's University Hospital
New Brunswick
New Mexico
University of New Mexico Health Sciences Center
Albuquerque
New York
Columbia University
New York
Columbia University (Pregnancy)
New York
Icahn School of Medicine at Mount Sinai
New York
NewYork-Presbyterian Hospital
Queens
Ohio
Good Samaritan Hospital
Cincinnati
Case Western Reserve University
Cleveland
Metrohealth System
Cleveland
The MetroHealth System (Pregnancy Cohort)
Cleveland
University Hospitals MacDonald's Women's Hospital
Cleveland
The Ohio State University - Wexner Medical Center
Columbus
Miami Valley Hospital
Dayton
Oklahoma
University of Oklahoma Health Sciences Center (OUHSC)
Oklahoma City
Pennsylvania
University of Pennsylvania
Philadelphia
University of Pittsburgh Medical Center (UPMC)
Pittsburgh
Rhode Island
Women & Infants Hospital
Providence
South Carolina
Prisma Health Upstate
Greenville
South Dakota
Sanford Health
Sioux Falls
Texas
St. David's Health Care
Austin
University of Texas Medical Branch (UTMB) Galveston
Galveston
Memorial Hermann Health System
Houston
University of Texas Health Science Center at Houston
Houston
UTMB Health League City Campus Hospital & Clinics
League City
University of Texas Health Science Center at San Antonio
San Antonio
Utah
McKay-Dee Hospital
Ogden
Utah Valley Regional Medical Center
Provo
Bateman Horne Center
Salt Lake City
Intermountain Medical Center (Intermountain Healthcare)
Salt Lake City
LDS Hospital - Intermountain Healthcare
Salt Lake City
University of Utah
Salt Lake City
University of Utah Health
Salt Lake City
Washington
Providence Regional Medical Center Everett
Everett
Institute for Systems Biology (ISB)
Seattle
Swedish Medical Center
Seattle
University of Washington
Seattle
Providence Sacred Heart Medical Center
Spokane
Wisconsin
Medical College Of Wisconsin
Milwaukee
West Virginia
West Virginia University
Morgantown
Other Locations
Puerto Rico
Hispanic Alliance for Clinical and Translational Research
San Juan
Time Frame
Start Date: 2021-10-29
Completion Date: 2025-05-23
Participants
Target number of participants: 15178
Treatments
Participants with SARS-CoV-2 Infection
Participants without SARS-CoV-2 Infection
Sponsors
Leads: NYU Langone Health
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)

This content was sourced from clinicaltrials.gov